The author of Memes for Mummyji: Making Sense of Post-Smartphone India on digital activism and how everyone is now a broadcaster ...
Barchart on MSN
Cathie Wood bets $19 million on 5 beaten-down stocks
In a volatile market, savvy investors like Cathie Wood take the opportunity to accumulate shares of companies with long-term potential. As the founder and CEO of ARK Invest, Wood is known for her high ...
CGI Inc. (NYSE:GIB) is among the 10 Best Magic Formula Stocks for 2026. On February 24, the company announced that its subsidiary, CGI Federal Inc., had secured a $64 million indefinite ...
Now, Invincible season 4 is on the horizon, promising even more brutal action. How will our "Invincible" heroes and villains ...
Pigeons are one of the most underestimated animals on Earth. Take them hundreds of miles away, release them into unfamiliar ...
7d
The New Eklavya: Why The Modern Learner Refuses To Bow, Yet Secretly Craves A Hand On The Shoulder
Because in today’s world, giving the thumb away is no longer a sign of obedience or respect. It’s about giving away your most significant advantage—in addition to the biometric key to your phone, your ...
Compass International Holdings has named a new president of the Compass brokerage operation. In a LinkedIn post on Monday night, Robert Reffkin, the CEO and chairman of Compass International Holdings, ...
Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...
In February 2020, Compass Coffee’s founders put together a presentation for potential investors in their Washington-based company. The deck laid out the owners’ vision: Michael Haft and Harrison ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways on ...
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A psychedelic medicine for hard-to-treat depression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results